Investors & Media


Ublituximab, A Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb),
In Combination With TGR-1202, A Next Generation Once Daily PI3k delta Inhibitor, Demonstrates Activity In Heavily Pre-Treated And High-Risk CLL And B-Cell Lymphoma
Dec 9, 2014
8:30 AM PT
Speaker: Matthew Lunning, DO

o Oral Session: 801
o Session: 624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Indolent B-cell NHL and T-cell NHL
o Date and Time: Tuesday, December 9, 2014 at 8:00am, during 7:30 - 9:00 AM PT Session
o Location: West Building, 2005-2007-2018-202

PDF View Presentation  680.8 KB   Add to Briefcase

Back to previous page